Drug therapy of ventricular tachycardia: a cost comparison of randomized noninvasive and invasive approaches.

The lower initial hospital costs of the noninvasive approach are offset by greater follow-up costs. Within two years the costs of the two approaches are equivalent. Thus, greater antiarrhythmic efficacy can be achieved by the invasive approach to drug selection without increasing total hospital costs.